Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Top Industry Exec Scott Moore Appointed CEO of EW Nutrition USA

Scott Moore comes to EW Nutrition USA on the heels of his tenure as President of North America operations for Hamlet Protein Inc. With decades of experience in top positions for Novus, Novartis, Perdue,...

NVS : 97.24 (-0.40%)
Global Acute Kidney Injury Treatment Market Provides An In-Depth Insight Of Sales Analysis| Pfizer Inc, Ipsen SA and Novartis AG

Global Acute Kidney Injury Treatment Market (Revenue and Volume), Type, Application, End-User, and Regional Analysis, Import-Export Analysis, Industry Analysis, Premium Insights, Intellectual Property...

CNAT : 0.44 (unch)
IPSEY : 18.2100 (+1.17%)
MRK : 82.96 (+0.38%)
NVS : 97.24 (-0.40%)
PFE : 36.63 (+0.33%)
TEVA : 12.09 (-1.06%)
VRX.TO : 30.80 (-3.33%)
Acute Otitis Media Treatment Market Analysis, Size, Share, Growth, Trends and Forecast to 2029

The research study on Global Acute Otitis Media Treatment market 2019 presents an extensive analysis of current Acute Otitis Media Treatment market size, drivers, trends, opportunities, challenges, as...

ABT : 89.36 (-0.33%)
BAYRY : 21.0200 (+0.24%)
LLY : 141.24 (+0.09%)
GSK : 43.41 (-0.75%)
NVS : 97.24 (-0.40%)
PDP.VN : 0.300 (+1.69%)
Global Esophageal Cancer Drugs Market 2019 Industry, Share, Demands, Size, Trends, Key Players, Growth, Gross Margin, Revenue, Value Chain, Innovation, and Forecast Analysis till 2025

KDMI offers a six-year forecast for the between 2019 and 2025. By value, the Esophageal Cancer Drugs market is anticipated to flourish at a significant CAGR during the forecast period i.e. 2020 and 2025....

AMGN : 222.85 (-0.28%)
BMY : 66.93 (+0.83%)
LLY : 141.24 (+0.09%)
GSK : 43.41 (-0.75%)
NVS : 97.24 (-0.40%)
Novartis receives EC Approval for Beovu(R), a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide

- Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading phase1...

NVS : 97.24 (-0.40%)
AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.

AZN : 48.79 (+1.96%)
MRK : 82.96 (+0.38%)
NVS : 97.24 (-0.40%)
VRTX : 243.27 (-0.23%)
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review

Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.

GILD : 67.18 (-0.56%)
MRK : 82.96 (+0.38%)
NVS : 97.24 (-0.40%)
BMY : 66.93 (+0.83%)
Carrols Restaurant Group, Inc. Names Markus Hartmann as General Counsel

Carrols Restaurant Group, Inc. ("Carrols" or the "Company") (Nasdaq: TAST) today announced that it has appointed Markus Hartmann as the Company's Vice President and General Counsel effective February 18,...

TAST : 5.17 (+1.37%)
DDAIF : 46.6800 (-0.19%)
NVS : 97.24 (-0.40%)
China Medical System (867.HK) Armed against Short Selling! The Biggest CSO Took Control of Full Industrial Chain

The short-selling company Blue Orca Capital would not have expected that its confrontation with China Medical System Holdings Limited ("China Medical System") actually helped the company. The confrontation...

MRK : 82.96 (+0.38%)
NVS : 97.24 (-0.40%)
Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales

Incyte (INCY) beats on earnings & sales in the fourth quarter on strong Jakafi growth.

REGN : 400.00 (+0.11%)
INCY : 78.99 (+0.69%)
LLY : 141.24 (+0.09%)
NVS : 97.24 (-0.40%)
Monofocal IOLs Market Trends 2020: Drivers, Strategies, Segmentation Application, Technology & Market Analysis Research Report to 2025

An analysis of Global has been provided within the latest report launched by Big Market Research that primarily focuses on the market trends, demand spectrum, and future prospects of this industry over...

CZMWF : 132.2000 (-0.97%)
HOCPF : 96.1000 (-0.16%)
NVS : 97.24 (-0.40%)
STAA : 36.91 (-0.78%)
VRX.TO : 30.80 (-3.33%)
Cataract Surgery Devices Market Enhancement in Medical Sector 2020 : Abbott Laboratories(NYS:ABT), Novartis AG(OTC:NVSEF), Carl Zeiss Meditec AG

The Global report centers around giving admirably examined information on the Cataract Surgery Devices market request and supply proportion, the fare/import situation, and the present and future development...

AGN : 198.17 (-0.08%)
CZMWF : 132.2000 (-0.97%)
GKOS : 67.33 (-4.01%)
NVS : 97.24 (-0.40%)
STAA : 36.91 (-0.78%)
TOPCF : 11.9050 (-0.04%)
VRX.TO : 30.80 (-3.33%)
ABT : 89.36 (-0.33%)
NVSEF : 96.0500 (-1.79%)
Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study

Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer....

JNJ : 150.61 (+0.32%)
PFE : 36.63 (+0.33%)
NVS : 97.24 (-0.40%)
VRTX : 243.27 (-0.23%)
Ophthalmology Drugs and Devices Market Size Industry Leaders & New Revenue Pockets – 2027

Market Study Report Has Added A New Report On Ophthalmology Drugs And Devices Market That Provides A Comprehensive Review Of This Industry With Respect To The Driving Forces Influencing The Market Size....

AGN : 198.17 (-0.08%)
GSK : 43.41 (-0.75%)
NVS : 97.24 (-0.40%)
RHHBY : 43.3900 (-0.66%)
SNPHF : 19.3000 (-0.26%)
VRX.TO : 30.80 (-3.33%)
Topical Drug Delivery System Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2020 to 2027

MENAFN12022020007010238ID1099690406

CRRTF : 0.7500 (+0.68%)
JNJ : 150.61 (+0.32%)
NVS : 97.24 (-0.40%)
VRX.TO : 30.80 (-3.33%)
Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance

The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.

GILD : 67.18 (-0.56%)
GSK : 43.41 (-0.75%)
NVS : 97.24 (-0.40%)
KNSA : 17.33 (-5.09%)
Lilly Reports Disappointing Data on Alzheimer's Candidate

Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.

BIIB : 340.32 (+2.20%)
RHHBY : 43.3900 (-0.66%)
LLY : 141.24 (+0.09%)
NVS : 97.24 (-0.40%)
Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA

The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.

AZN : 48.79 (+1.96%)
MRK : 82.96 (+0.38%)
INCY : 78.99 (+0.69%)
NVS : 97.24 (-0.40%)
Stomach Cancer/Gastric Cancer Treatment Market to Reach USD 8.20 Billion by 2026; Rapid Adoption of PD-1 Inhibitors for Treating Gastric Cancers to Boost the Market: Fortune Business Insights(TM)

The global Stomach Cancer Treatment Market size is expected to reach USD 8.20 billion by 2026, exhibiting a CAGR of 15.3% during the forecast period. One of the major forces behind the rise of this market...

BAYRY : 21.0200 (+0.24%)
LLY : 141.24 (+0.09%)
MRK : 82.96 (+0.38%)
NVS : 97.24 (-0.40%)
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review

- FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)1

NVS : 97.24 (-0.40%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -1.69 , SEDG -0.56 , THC +0.10 , TER -2.25 , LITE -2.11
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar